Bausch + Lomb (BLCO) Reports Q1: Everything You Need To Know Ahead Of Earnings

Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings tomorrow before market open. Here’s what you need to know.

Bausch + Lomb beat analysts’ revenue expectations by 1.8% last quarter, reporting revenues of $1.28 billion, up 9.1% year on year. It was a mixed quarter for the company, with a decent beat of analysts’ EPS estimates but full-year revenue guidance slightly missing analysts’ expectations.

Is Bausch + Lomb a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Bausch + Lomb’s revenue to grow 4.2% year on year to $1.15 billion, slowing from the 18% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.02 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Bausch + Lomb has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 3.8% on average.

Looking at Bausch + Lomb’s peers in the healthcare equipment and supplies segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Integer Holdings delivered year-on-year revenue growth of 7.3%, beating analysts’ expectations by 2%, and Penumbra reported revenues up 16.3%, topping estimates by 2.7%. Integer Holdings traded up 2.6% following the results while Penumbra was also up 7.2%.

Read our full analysis of Integer Holdings’s results here and Penumbra’s results here.

Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 5.2% on average over the last month. Bausch + Lomb is down 5.8% during the same time and is heading into earnings with an average analyst price target of $18.29 (compared to the current share price of $13.66).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.